Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 108960
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108960
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108960
Rapid cholestasis improvement as key strategy for steroid-refractory immune-related cholangitis: A case report
Zhao Gao, Shi-Kai Wu, Xuan Jin, Department of Medical Oncology, Peking University First Hospital, Beijing 100034, China
Ji-Xin Zhang, Department of Pathology, Peking University First Hospital, Beijing 100034, China
Xiao-Dong Tian, Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China
Author contributions: Gao Z and Jin X wrote the manuscript; Wu SK, Jin X and Tian XD were responsible for managing the patient, conducting the clinical diagnosis and treatment, and gathering data; Gao Z and Jin X oversaw the patient’s diagnosis and treatment, composition and submission of the manuscript; Zhang JX conducted diagnoses on patients' pathological puncture specimens and was responsible for the collection of pathological images. All authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors have no relevant financial or non-financial interests to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xuan Jin, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. jinxuanbdyy@outlook.com
Received: April 28, 2025
Revised: June 16, 2025
Accepted: August 7, 2025
Published online: September 15, 2025
Processing time: 142 Days and 2 Hours
Revised: June 16, 2025
Accepted: August 7, 2025
Published online: September 15, 2025
Processing time: 142 Days and 2 Hours
Core Tip
Core Tip: Steroid-refractory immune-related cholangitis, characterized by biliary obstruction, can be caused by drugs such as immune checkpoint inhibitors (ICIs). While there a few reports of sclerosing cholangitis after ICI administration, the therapeutic importance of local relief of obstruction has not been reported. Stent implantation provides rapid relief from cholestasis and is an effective approach to the treatment of immune-related cholangitis.